EGFR and lung carcinoma: For example, in advanced lung cancer, smoking status is linked to higher mutational burden, higher rates of C > A transversion mutations, and increased frequency of EGFR alterations, the latter having subsequent impact on selection of EGFR-directed therapies [2–4].